Scarica l'app Stockscreener
86.34
0.17%
-0.15
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARWR Giù?
Forum
Previsione
Frazionamento azionario
Arrowhead Pharmaceuticals Inc Borsa (ARWR) Ultime notizie
Arrowhead Pharmaceuticals director sells $173,920 in stock - Investing.com
Arrowhead Pharmaceuticals (ARWR) Director Adeoye Olukotun Sells 2,000 Shares - GuruFocus
Arrowhead (ARWR) Stock: Slides 3.28% to $86.47 in the Latest Reading; Technical Setup: the $82.15 to $90.79 Range Remains in Focus at the CloseHigh Dividend Factor - Vinanet
Arrowhead Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ARWR - TradingView
Arrowhead (NASDAQ: ARWR) director to sell 2,000 shares - Stock Titan
Arrowhead (NASDAQ: ARWR) director to sell 11,600 shares - Stock Titan
ARWR Looks 53.4% Overvalued on GF Value™ - GuruFocus
People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides - Arrowhead Pharmaceuticals, Inc.
ETFs Investing in Arrowhead Pharmaceuticals, Inc. Stocks - TradingView
Arrowhead Pharmaceuticals Earnings Call Signals Confident Expansion - TipRanks
Empowered Funds LLC Buys 119,202 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
ARWR Stock Clocks Best Day In Nearly 8 Months As Analyst Lifts Price Target On Plozasiran Data - Stocktwits
Avoro Capital discloses 9.64% Arrowhead Pharmaceuticals (ARWR) stake including warrants - Stock Titan
Arrowhead Pharmaceuticals, Inc.: Revenue and Earnings Analysts Forecasts Revisions | HDP1 | US04280A1007 - marketscreener.com
Why Arrowhead Pharmaceuticals (ARWR) Is Back In The Spotlight - Sahm
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Analysis: A Biotech Gem with 24.74% Upside - DirectorsTalk Interviews
Assenagon Asset Management S.A. Grows Stock Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
How Investors Are Reacting To Arrowhead Pharmaceuticals (ARWR) Soaring Sales But Deepening Losses - simplywall.st
FY2026 Earnings Estimate for ARWR Issued By HC Wainwright - MarketBeat
Zacks Research Analysts Increase Earnings Estimates for ARWR - MarketBeat
Pacer Advisors Inc. Invests $1.50 Million in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Expected to Rise, HC Wainwright Analyst Says - marketbeat.com
Morgan Stanley Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $120 - Moomoo
Arrowhead Pharmaceuticals (ARWR) Stock Retreats As Losses Deepen Behind Phase III Progress - simplywall.st
Arrowhead Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $110.2, Implies 23% Upside - TradingView
Arrowhead Pharmaceuticals Inc (ARWR) (Q3 2026) Earnings Call Highlights: Strong Phase III Data ... - Yahoo Finance
Arrowhead Pharmaceuticals Q3 Earnings Call Highlights - marketbeat.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Announces Quarterly Earnings Results - MarketBeat
Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results - Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Arrowhead Pharmaceuticals Inc.R (HDP1.DU) Q3 FY2026 earnings call transcript - Yahoo Finance
Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher - Arrowhead Pharmaceuticals, Inc.
The Manufacturers Life Insurance Company Has $10.06 Million Stake in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
California State Teachers Retirement System Has $9.05 Million Stock Position in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Purchased by Dimensional Fund Advisors LP - MarketBeat
FDA voucher could put Arrowhead's planned drug filing on a six-month review track - Stock Titan
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)August 3, 2026 - BioSpace
Arrowhead Pharmaceuticals, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh - TradingView
Janus Henderson Group PLC Acquires 156,544 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Vanguard unit discloses 6.38M Arrowhead (ARWR) shares, a 4.53% stake - Stock Titan
The Bull Case For Arrowhead Pharmaceuticals (ARWR) Could Change Following Dual Phase 3 RNAi Cardiometabolic Milestones - Yahoo Finance
Arrowhead Pharmaceuticals, Inc. $ARWR Position Cut by Arrowstreet Capital Limited Partnership - MarketBeat
Arrowhead Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $105.4, Implies 23% Upside - TradingView
Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia - BioSpace
Arrowhead Pharmaceuticals Advances Zodasiran Study for HoFH Trea - GuruFocus
Arrowhead Pharmaceuticals Inc - TradingKey
BlackRock discloses 10.1% Arrowhead Pharmaceuticals (ARWR) stake in latest 13G/A - Stock Titan
ARWR Stock On Track To Hit Over 5-Year Highs – Retail Cheers Phase 3 Breakthrough As Arrowhead Targets Broader FDA Approval - Stocktwits
Arrowhead Pharmaceuticals (ARWR) Completes Enrollment in YOSEMITE Trial - GuruFocus
H.C. Wainwright raises Arrowhead Pharma price target to $115 on trial data - Investing.com Canada
Arrowhead's Rare Cholesterol Disease Study Reaches 70 Patients - Stock Titan
Arrowhead Pharmaceuticals Inc (ARWR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Arrowhead Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Arrowhead Pharmaceuticals, Inc. Revenue Breakdown – BX:HDP1 - TradingView
Allspring Global Investments Holdings LLC Purchases 47,902 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals, Inc. Revenue Breakdown – XETR:HDP1 - TradingView
Is Arrowhead Pharmaceuticals on the Cusp of a Major Breakout - Kavout | AI
Arrowhead Pharmaceuticals Surges as Plozasiran Advances Toward Expanded ApprovalEarnings Revision Downgrade - Vinanet
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Forecasts - Yahoo! Finance Canada
The 'Best-Case Scenario' That Shot Arrowhead Stock Sky-High - Investor's Business Daily
Is Arrowhead Pharmaceuticals Stock A Smart Buy After Its Transition To A Commercial Company? - Trefis
ARWR Reiterated by Piper Sandler -- Price Target Raised to $126 - GuruFocus
H.C. Wainwright reiterates Arrowhead Pharma stock rating on trial data By Investing.com - Investing.com Canada
Arrowhead shares surge as Phase III plozasiran studies deliver positive pancreatitis data - The Pharma Letter
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):